{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-031684","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2024-10-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.088726+00:00","generated_at":"2026-05-30T11:40:18.396187+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Monopar presents positive uPAR radiopharma dosimetry data at EANM 2024","bullets":["MNPR-101-Lu shows favorable organ safety at high Lu-177 doses using human Zr-89 dosimetry data.","Presentation accepted as 'Top-Rated Oral Presentation' at EANM 2024 in Hamburg, Germany.","Preclinical and clinical data show favorable biodistribution, tumor uptake, and low off-target binding.","MNPR-101-Lu ongoing Phase 1a trial (NCT06617169); MNPR-101-Zr imaging trial (NCT06337084)."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-031684","json":"https://secwatch.observer/filing/0001437749-24-031684.json","markdown":"https://secwatch.observer/filing/0001437749-24-031684.md","text":"https://secwatch.observer/filing/0001437749-24-031684.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924031684/0001437749-24-031684-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924031684/mnpr20241021c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T11:40:18.396187+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}